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Rhodococcus equi is an unusual zoonotic pathogen that can cause life-threatening diseases in susceptible hosts. Twelve patients
with R. equi infection in Kentucky were compared to 137 cases reported in the literature. Although lungs were the primary
sites of infection in immunocompromised patients, extrapulmonary involvement only was more common in immunocompetent
patients (𝑃 < 0.0001). Mortality in R. equi-infected HIV patients was lower in the HAART era (8%) than in pre-HAART era
(56%) (𝑃 < 0.0001), suggesting that HAART improves prognosis in these patients. Most (85–100%) of clinical isolates were
susceptible to vancomycin, clarithromycin, rifampin, aminoglycosides, ciprofloxacin, and imipenem. Interestingly, there was a
marked difference in susceptibility of the isolates to cotrimoxazole between Europe (35/76) and the US (15/15) (𝑃 < 0.0001).
Empiric treatment of R. equi infection should include a combination of two antibiotics, preferably selected from vancomycin,
imipenem, clarithromycin/azithromycin, ciprofloxacin, rifampin, or cotrimoxazole. Local antibiograms should be checked prior
to using cotrimoxazole due to developing resistance.
1. Introduction
Rhodococci are aerobic, Gram positive, pleomorphic, and
nonmotile bacteria, which can be detected in soil and grow
well on simple nutrients provided by herbivore manure.They
also grow well in the intestines of grazing animals. Among
the organisms making up the genus Rhodococcus, R. equi is
the most common isolate and has been well recognized as
an important pathogen in veterinary medicine. It can cause
bronchopneumonia, especially in foals [1]. R. equi was first
isolated from foals with bronchopneumonia in 1923 [2]. The
genus Rhodococcus is now known to be distinct from the
other closely related species of acid-fast or modified acid-fast
organisms of the genera Gordonia, Nocardia, and Mycobac-
terium [3].
The vastmajority of human infections with theRhodococ-
cus spp. are caused by R. equi [4], whereas there have been
case reports of human infection by the other species [5–
7]. The first human case of R. equi infection was described
by Golub et al. in 1967 in a 29-year-old male with plasma
cell hepatitis on chronic steroid therapy who presented with
cavitary pneumonia [8]. Frequency of infection with R. equi
increases in immunocompromised individuals such as those
with AIDS and organ transplants [9]. Since the first case of
R. equi infection in an AIDS patient in 1986 [10], there have
been increasing numbers of infections with this bacterium
reported in AIDS patients [9]. Emergence of resistance to
macrolides and rifampin has beenwell documented inR. equi
isolated from animals. However, there is no systematic infor-
mation available regarding antibiotic resistance of R. equi
isolates fromhumans. In addition, there is no standard antibi-
otic susceptibility testing panel for R. equi in humans. The
main objective of the present study is to summarize disease
characteristics and antibiotic susceptibility testing results in
12 cases of R. equi infection at a tertiary care center in Central
Kentucky and compare with the cases of the infection with
this pathogen in the United States and Europe reported in
the literature to generate systematic information on clinical
diseases associated with R. equi infection and antibiotic
susceptibility of the bacterium isolated from the patients.
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2. Methods
2.1. Identification of Patients with R. equi Infection at the
University of Kentucky. Following IRB approval, themicrobi-
ology laboratory database was used to identify subjects from
whom R. equi was isolated in the period from January 1998
to December 2013. A SUNQUEST Epi report was generated
searching forRhodococcus equi in the result field. Other infor-
mation collected in this report included subject name, medi-
cal record number, specimen source, date of specimen collec-
tion, and antibiotic susceptibility test results for the isolate. A
total of 14 subjects were identified from whom R. equi was
isolated. Among these isolates, the results of antibiotic sus-
ceptibility testing were available for 11 subjects. Chart review
was performed on 12 of the 14 subjects to gather age, gender,
occupational exposure to animals, HIV status, viral load,
CD4 count, clinical and radiographic features, and antibiotic
treatment and outcomes. Two subjects were from a referral
hospital and their medical records were not available for
review.
Identification of R. equi was performed by BD Phoenix
Automated Microbiology System (Becton, Dickinson and
Company, New Jersey). Screening of antibiotic susceptibility
for these clinical isolates was performed by Epsilometer-test
(E-test) (BioMérieux, Durham, NC). The interpretive crite-
rion for determining susceptibility to antibiotics followed the
CLSI Guidelines in the M100 document for Staphylococcus
aureus, with the inclusion of results for vancomycin and
rifampin [17]. Break points for ciprofloxacin and levofloxacin
were interchangeable. Clarithromycin was used as a class
representative for newer macrolides.
2.2. Literature Search on Cases of R. equi Infection. PubMed
search was performed using key words “Rhodococcus equi”
and “Corynebacterium equi” (an older, now obsolete name for
the organism). The articles containing these key words were
then filtered by using additional key words “Humans” and
“English language”. Abstracts of these studies were reviewed
and any study describing at least 10 cases was included in this
study. There were four European studies [11–13, 16] and two
United States (US) studies [14, 15] that satisfied this require-
ment. Antibiotic susceptibility data were not available in one
of the two US studies [15].
2.3. Statistical Analyses. Statistical significances of the differ-
ences in clinical features between groups of patients and in
antibiotic susceptibility of clinical isolates were determined
by Fisher's exact test. In the analyses of the differences in
antibiotic susceptibility, “corrected” 𝑃 values were calculated
by multiplying each 𝑃 value by the number of antibiotics
studied [18].
3. Results
3.1. Case Series at the University of Kentucky. There were
twelve cases in this series including six patients positive
for human immune deficiency virus (HIV), two with organ
transplant, and four immune competent individuals (Table 1).
Two of the immune competent patients had wound infection
with R. equi and the other two had pneumonia. All eight
immunocompromised patients had pneumonia. R. equi-
infected patients presented with varying symptoms depend-
ing on organ system involved (Table 1). Most common symp-
toms were fever, cough, dyspnea, anorexia, and weight loss
in patients diagnosed with pneumonia. R. equi was isolated
from respiratory specimens in 7 patients and from the periph-
eral blood from 5 patients. R. equi was also isolated from
wound cultures from two immunocompetent individuals.
Among the 10 cases with R. equi pneumonia, bacteremia
was noted in five patients, one immunocompetent and four
immunocompromised. A cavitary lesion was noted in radio-
graphic imaging in 4 of the 10 patients.Three of these patients
had upper lobe cavitary lesions and one had lower lobe cavita-
tion.The presence of the cavitary lesion did not correlate with
the presence of bacteremia. All six patients with HIV infec-
tionwere not on antiretroviral therapy at the time of diagnosis
of R. equi infection; 5 of them were antiretroviral therapy
(ART) näıve and the other patient stoppedART a fewmonths
prior to diagnosis of R. equi infection. ART was initiated in
all the patients after the diagnosis of R. equi infection at out-
patient follow-up. One patient was consistently nonadherent
with ART and other medications and finally succumbed to
infection after one year of initial diagnosis of R. equi pneu-
monia.
In the two organ transplant patients with R. equi infec-
tion, one had received a lung transplant and the other had
received a renal transplant. Both the transplant patients were
treated successfully with prolonged course of antibiotics and
they did not have any recurrence of infection.
In the immunocompetent patients, treatment of the two
individuals with wound infection was successful. The other
two individuals with R. equi pneumonia did not follow up in
the university health system. Based on social security death
index data, one patient died after 6 months and the other
patient expired after 15 months, both from unknown causes.
3.2. Review of Clinical Characteristics of Infection with R. equi
inThis Study andCases in the Literature. Theepidemiological
and clinical characteristics of subjects infected with R. equi
were analyzed for four European studies [11–13, 16] and three
US studies including two studies in the literature [14, 15] and
the present study.
In the four European studies, all 113 patients were immun-
ocompromised with HIV infection. Among these patients,
107 subjects (95%) had pulmonary disease with or without
extrapulmonary R. equi infection, and six subjects had
extrapulmonary involvement only (Table 2). In the three US
studies including the present study, 21 immunocompromised
subjects (95%) had pulmonary diseaseswith orwithout extra-
pulmonary involvement and one subject had extrapulmonary
involvement only (Table 2). Therefore, there is no significant
difference in the organ system involvement in infection with
R. equi in the immunocompromised patients between the
European and US subjects.
In contrast, in the cases of R. equi infection in immuno-
competent individuals in the US, only 5 of 14 patients
had pulmonary diseases with or without extrapulmonary
involvement, and the other 9 patients had extrapulmonary
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Table 2: Organ systems involved in infectionwithR. equi in immunocompromised and immunocompetent patients in Europe and theUnited
States.
Immune status Europe
∗ United States†
Pulmonary ± extrapulmonary Extrapulmonary only Pulmonary ± extrapulmonary Extrapulmonary only
Immunocompromised 107/113‡ (95%) 6/113 (5%) 21/22 (95%) 1/22 (5%)
Immunocompetent 0 0 5/14 (36%) 9/14 (64%)§
∗From Arlotti et al. [11], Donisi et al. [12], Topino et al. [13], and Torres-Tortosa et al. [16].
†From Scott et al. [14], Verville et al. [15], and the 12 cases in Central Kentucky reported in the present study.
‡Number of patients with the organ involvement/total number of patients.
§
𝑃 = 0.0002 when compared to immunocompromised patients in the US and 𝑃 < 0.0001 when compared to immunocompromised patients in Europe.
Table 3: Comparison of organ system involvement, sites of clinical isolation, and radiographic findings in R. equi infection in the seven
studies under analysis.
Studies
Number of
patients
Site of isolation∗ Organ system involved Radiographic findings
Respiratory
specimen
(%)
Blood (%) Other†
Pulmonary ±
extrapulmonary
(%)
Extrapulmonary
only (%)
Pneumonia
on imaging
Cavitary
lesion (%)
Europe
Donisi et al. [12] 12 4 (25) 10 (63) 2 (12) 9 (75) 3 (25) 9 5 (56)
Arlotti et al. [11] 24 21 (51) 13 (32) 7 (17) 24 (100) 0 (0) 24 18 (75)
Torres-Tortosa et al. [16] 67 64 (52) 34 (27) 26 (21) 65 (97) 2 (3) 65 45 (49)
Topino et al. [13] 10 5 (38) 8 (62) 0 (0) 9 (90) 1 (10) 9 6 (67)
Subtotal 113 94 (48) 65 (34) 35 (18) 107 (95) 6 (5) 107 74 (69)
United States
Verville et al. [15] 12 8 (53) 5 (33) 2 (13) 8 (67) 4 (33) 8 6 (75)
Scott et al. [14] 12 6 (35) 7 (41) 4 (24) 8 (67) 4 (33) 8 7 (88)
University of
Kentucky 12 7 (47) 5 (33) 3 (20) 10 (83) 2 (17) 10 4 (40)
Subtotal 36 21 (45) 17 (36) 9 (19) 26 (72) 10 (28) 26 17 (65)
Total 149 115 (48) 82 (34) 44 (18) 133 (89) 16 (11) 133 91 (68)
∗Total numbers of specimens are more than numbers of patients as R. equi was isolated from a variety of specimens.
†Bone, joint fluid, abscess, wound, pleura and pericardial fluid, liver, brain, cerebral spinal fluid, stool, and skin.
involvement only (Table 2). Extrapulmonary sites of infection
included central nervous system, bone, blood, eyes, and soft
tissue.The frequency of extrapulmonary involvement only in
the immunocompetent patients (9/14 cases) was significantly
higher when compared to the frequencies of those in the
immunocompromised patients in the US (1/21) and those
(6/113) in European studies (𝑃 = 0.0002 for US and 𝑃 <
0.0001 for European studies; Table 2).
In patientswith pneumonia, among the 107 subjects in the
European studies, 74 (69%) had cavitary lesions in the lungs
(Table 3). Similarly, 17 of 26 subjects (65%) in the US studies
whowere diagnosedwith pneumonia presentedwith cavitary
lesions (Table 3).
The outcome of R. equi infection in HIV-positive patients
depended strongly upon treatment of HIV with highly active
antiretroviral therapy (HAART). Among the total 113 HIV-
positive subjects in the European studies, 93 were diagnosed
in the pre-HAART era and 20 were diagnosed in the HAART
era. Mortality was 56% (52/93) in pre-HAART era while it is
only 5% (1/20) in HAART era (Table 4, 𝑃 < 0.0001). The out-
come in two additional subjects diagnosed with R. equi infec-
tion in pre-HAART era was unknown. Therefore, HAART
significantly improved survival in HIV-positive patients with
R. equi infections. A similar tendency was observed in the
US studies. Among 12 HIV-positive patients diagnosed with
R. equi infection in pre-HAART era, 7 of them (58%) died,
whereas mortality was only 1 of 6 patients (17%) diagnosed
in HAART era (Table 4). However, the difference in the
mortality between pre-HAART and HAART era in the US
studies did not reach statistical significancemost likely due to
the small number of patients available in the analysis. When
the data from the European and US studies are combined,
mortality in R. equi-infected HIV patients was higher in the
pre-HAART era (56%, 59/105) than inHAART era (8%, 2/26)
(𝑃 < 0.0001).
3.3. Review of Antibiotic Susceptibility of R. equi Isolated
from Patients in the Present Study and in the Literature. The
method of antibiotic susceptibility testing and minimum
inhibitory concentration (MIC) breakpoints assessment are
not described in all of the 6 studies that were analyzed. E-test
was used in the study byArlotti et al. [11] and the present study
at the University of Kentucky. There were significant dif-
ferences in the panel of antibiotics chosen for susceptibility
BioMed Research International 5
Table 4: Comparison of mortality in R. equi-infected HIV+ patients in pre-HAART and HAART era in the seven studies under analysis∗.
Studies Total HIVpatients
Diagnosed
before 1997
(pre-HAART
era)
Diagnosed in or
after 1997
(HAART era)
Patients died
(%)
(pre-HAART
era)
Patients died
(%) (HAART
era)
Europe∗ 113 93 20 52 (56) 1 (5)
United States† 18 12 6 7 (58) 1 (17)
Total 131 105 26 59 (56) 2 (8)
∗From Arlotti et al. [11], Donisi et al. [12], Topino et al. [13], and Torres-Tortosa et al. [16].
†From the cases in the Central Kentucky reported in the present study, Scott et al. [14], and Verville et al. [15].
testing as these studies span over two decades. Antibiotics
for which susceptibility testing was performed in most
studies included vancomycin, erythromycin/clarithromycin,
cotrimoxazole, rifampin, penicillin, ciprofloxacin, and gen-
tamicin. Twenty-one antibiotics were selected for which
susceptibility data were available for at least 10 isolates of R.
equi. These are listed in the order of higher susceptibility in
Table 5. At least 85% of R. equi isolates were susceptible to
10 of the 21 antibiotics evaluated. These ten antibiotics are
clarithromycin, vancomycin, rifampin, amikacin, erythro-
mycin, teicoplanin, imipenem, netilmicin, gentamicin, and
ciprofloxacin. In contrast, R. equi isolates were consistently
resistant to penicillin, oxacillin, ampicillin, cephalothin, and
clindamycin, and their susceptibilities to these antibiotics
were lower than 15% (Table 5).
Inmost of the 21 antibiotics listed in Table 5, susceptibility
of the bacterium was similar among 6 studies including the
present study.This strongly suggests that methodological dif-
ferences in testing antibiotic susceptibility of R. equi isolates
in these 6 studies did not significantly affect the outcome of
the tests. However, there is amarked difference in susceptibil-
ity of the clinical isolates to cotrimoxazole between European
and US studies. One hundred percent (15/15 isolates) of R.
equi from the US were susceptible to cotrimoxazole, whereas
only 35 of 76 isolates (46%) from Europe were susceptible to
this compound (𝑃 < 0.0001, corrected𝑃 < 0.0018). A similar
tendency was also observed in susceptibility of the bacterium
to tetracycline. Nine of the 10 isolates (90%) from theUSwere
susceptible to tetracycline, whereas only 17 of 42 (43%) of
isolates from Europe were susceptible to this antibiotic (𝑃 =
0.0127). However, this difference did not reach statistical sig-
nificance when corrected for the number of variables tested
(corrected 𝑃 = 0.229). The difference in susceptibility of the
R. equi isolates to cotrimoxazole was not due to differences in
the sites of isolation of the bacterium from the patients in the
European and US studies, because a majority of the isolates
were from either the respiratory specimen (48% in Europe
and 45% in the US) or the peripheral blood (34% in Europe
and 36% in the US) (Table 3).
3.4. Empiric Treatment of R. equi Infection. Based on anti-
biotic susceptibility of the clinical isolates shown in Table 5,
R. equi infection in immunocompromised patients and the
serious infection in immunocompetent individuals should
receive intravenous therapy with 2 or 3 drugs that include
vancomycin, imipenem, clarithromycin/azithromycin, rifam-
pin, aminoglycoside, or ciprofloxacin/levofloxacin [9, 19].
Most patients require a minimum of 2 weeks of intravenous
therapy at which point oral therapy with 2 or 3 drugs that
include vancomycin, rifampin, or ciprofloxacin/levofloxacin
may be substituted based on clinical improvement [9, 20].
Immunocompetent patients with mild to moderate diseases
can be treated with two active oral agents [19]. Vancomycin
and imipenem are bactericidal agents that help decrease
high bacterial burden and rapid clearance of bacteremia [9,
16]. Clarithromycin, rifampin, ciprofloxacin, and vancomycin
achieve good intracellular concentrations and can be very
effective on intracellular pathogens [15, 19]. Cotrimoxazole is
an option for both intravenous and oral therapy but is recom-
mended for empiric therapy in the US but not in Europe due
to the high frequency of resistance of the R. equi isolates to
this antibiotic in Europe as described earlier.
4. Discussion
R. equi has been known to cause pneumonia in immunocom-
promised individuals since it was first reported in 1967 [8].
In the literature, 95–100% of immunocompromised patients
infected with the bacterium presented with pulmonary
involvement [11, 16]. In agreement with these findings, the
cases identified in Kentucky also presented with pulmonary
involvement for all eight immunocompromised subjects.This
was not the case for immunocompetent patients, however.
Only two of four (50%) immunocompetent subjects in the
currently described patient series had pulmonary involve-
ment. A similar tendency can be seen in other studies in the
US, in which pneumonia was observed only in 3 of 10 (30%)
infected immunocompetent patients [14, 15]. Therefore, it
is important to recognize that immunocompetent subjects
may not present with pneumonia when infected with R. equi
but instead may have localized infections such as cutaneous
wounds or osteomyelitis.
Since pulmonary involvement was observed in themajor-
ity of immunocompromised but not of immunocompetent
patients infected with R. equi, insufficient immune responses
appear to be a significant cause that makes individuals
susceptible to pulmonary infection with this bacterium. In
immunocompetent individuals, a local exposure of organ(s)
such as skin or a bone to the materials, possibly soil, highly
contaminated with R. equimay have caused these individuals
to be susceptible to the infection.
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In a review of the literature, cavitary lesions were detected
on radiologic imaging in 40–88% (mean 68%) of subjects
diagnosed with R. equi pneumonia. In the case series at the
University of Kentucky, 3 of 4 (75%) of patients with cavitary
lesions had the lesions of an upper lobe. Similar tendencies
were observed in other case series describing radiologic find-
ings in R. equi pneumonia [21, 22]. Therefore, the presence
of upper lobe cavitary lesions appears to be an important
differential feature of R. equi infection by imaging.
In this review, mortality of HIV patients infected with R.
equi is 56% in the pre-HAART era while it was only 8% in
HAART era. The study by Torres-Tortosa et al. [16] showed
improved survival in patients in whom HAART was started.
These results strongly suggest that the protective immune
responses are crucial, in addition to antibiotic treatment, to
eradicate R. equi and prevent mortality.
Studies using animals infected with R. equi have demon-
strated the importance of both cell-mediated and humoral
immune responses in clearing the bacterium [23]. It is well
recognized that innate immune cells such as neutrophils
and macrophages are crucial to control primary infection
[24]. Th1-type immune responses (IL-2, IL-12, IFN-𝛾, and
TNF-𝛼) are important for resistance to R. equi. Both CD4
and CD8 T cells produce IFN-𝛾 which is necessary to
activate macrophages to eliminate Rhodococcus from intra-
cellular locations. Rhodococcus-specific antibodies opsonize
the extracellular organisms to promote phagocytosis and
enhance bacterial killing [25]. This antibody-mediated pro-
tective mechanism is relevant because R. equi is a facultative
intracellular bacterium. For example, newborn foals are
exposed toR. equi infection soon after birth as it is ubiquitous
in soil. However, most of them do not develop clinical
infection until 6–12 weeks after birth, which coincides with
decreases of maternal antibodies in these animals.
In agreement with the importance of the protective
immunity to control R. equi in animal models, immunocom-
petent patients with R. equi infection treated with antibi-
otics have better outcomes in general when compared to
infected immunocompromised individuals [15, 26–29].How-
ever, there are case reports of deaths in immunocompetent
patients diagnosed with R. equi pneumonia [30, 31]. In the
current case series, two immunocompetent patients with R.
equi pneumonia died after six and fifteenmonths of discharge
from hospital, respectively, although the cause of death in
these patients is unknown as they were lost to follow-up.
Antibiotic treatment is essential to eliminate R. equi infection
not only in immunocompromised but also in immunocom-
petent individuals [30, 31]. Virulent strains of R. equi have
been shown to contain a plasmid, which encodes seven
related virulence associated proteins (Vaps) including the
immunodominant surface-expressed protein Vap A that is
essential for intracellular growth of the bacterium in macro-
phages [32, 33]. These virulence proteins may contribute to
reducing the efficiency of the protective immunity to control
the bacterium.
The present study made an interesting observation with
regard to antibiotic susceptibility to cotrimoxazole between
theUS and Europe. All clinical isolates in theUSwere suscep-
tible to cotrimoxazole, whereas more than half of the isolates
in Europe were resistant. This is the first time that this
difference has been reported. This difference in susceptibility
to cotrimoxazole may suggest that the US and Europe have
different strains of R. equi. It is unclear why and how the
bacterium in Europe acquired resistance to cotrimoxazole. It
is possible that differences in usage of antibiotics in domestic
animals between these two continents have resulted in the
disparity in susceptibility to the antibiotic.
Based on the consensus findings for antibiotic suscepti-
bility for clinical isolates, an empiric antibiotic treatment
regimen for R. equi infection would include 2-3 intrave-
nous agents (vancomycin, imipenem, clarithromycin/azith-
romycin, rifampin, an aminoglycoside, ciprofloxacin/lev-
ofloxacin, or cotrimoxazole), administered for at least 2weeks
if the patient is immunocompromised [9, 19], or 2 oral agents
(clarithromycin/azithromycin, rifampin, ciprofloxacin/lev-
ofloxacin, or cotrimoxazole) if the patient is immunocom-
petent with mild or moderate diseases [19]. Final antibiotic
choice should be determined based on in vitro antibiotic sus-
ceptibility testing results. Monotherapy for R. equi infection
is not recommended, as it is often ineffective. This infection
should be treated with at least two agents with activity against
R. equi. Parenteral therapy is generally recommended for
administration during the first few weeks of a 6-month
or longer course of treatment. One of these agents should
be bactericidal given the frequency with which it is iso-
lated from blood [34, 35] and one agent should be active
against intracellular organisms. R. equi is usually suscep-
tible to erythromycin and extended spectrum macrolides,
rifampin, fluoroquinolones, aminoglycosides, glycopeptides,
and imipenem [36]. Macrolides, fluoroquinolones, glycopep-
tides, and rifampin have the additional advantage of achiev-
ing good intracellular drug concentration [37]. In vitro stud-
ies showed combinations of gentamicin with erythromycin
or rifampicin had antagonistic effects on killing compared to
either drug alone, while combinations of erythromycin with
rifampicin or penicillin had synergistic effect [38].
In this case series at the University of Kentucky, one in
eight clinical isolates was resistant to rifampin. Recent studies
have shown emergence ofmacrolide and rifampin resistantR.
equi strains in horse breeding farms because of widespread
use of these antibiotics for prophylaxis and treatment [39].
Rifampin resistant R. equi strains were isolated from HIV
patients from northernThailand [40]. Rifampin resistance is
associated with mutations in rpo B gene. In view of this, a
combination of vancomycin and macrolide as initial empiric
therapy for R. equi infections is suggested. Aminoglycosides
have good activity against R. equi. However, they are falling
out of favor because of their toxicity profile. Among car-
bapenems, more data is available for imipenem than for
meropenem [11, 13, 16].
The duration of therapy depends on the site(s) and extent
of infection, underlying immunocompetence of the host, and
the clinical response to therapy. A minimum of 6 months of
antibiotic therapy is typically required for immunocompro-
mised patients with pulmonary, bone and joint, or central
nervous system infections [9]. Secondary prophylaxis with an
oral agent may be considered in patients who are on immune
suppressive agents or HIV patients with low CD4 count [9].
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Any improvement in the immunocompetence of the host
should be pursued as a therapeutic adjunct in treating R. equi
infections, either through curtailment of immunosuppressive
medications or through aggressive antiretroviral therapy.
In the present study, twelve patients with R. equi infection
inKentuckywere compared to 137 cases reported in the litera-
ture. In both the cases in Kentucky and those in the literature,
lungs were the primary sites of infection in immunocom-
promised patients, whereas extrapulmonary involvement
only was more common in immunocompetent patients. In
R. equi-infected immunocompromised patients with HIV,
HAART improves prognosis in these patients. Based on
antibiotic susceptibility of the bacterium isolated from the
patients, the empiric treatment of R. equi infection should
include a combination of two antibiotics, preferably selected
from vancomycin, imipenem, clarithromycin/azithromycin,
ciprofloxacin, rifampin, or cotrimoxazole. Local antibi-
ograms should be checked prior to using cotrimoxazole due
to developing resistance.
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